|Articles|October 14, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
4
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
5
